Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Total revenue	$ 32,061	$ 6,106	$ 75,003	$ 7,193
Operating costs and expenses
Cost of sales	177	0	371	0
Total operating costs and expenses	87,691	86,359	266,347	281,975
Loss from operations	(55,630)	(80,253)	(191,344)	(274,782)
Other income (expense), net
Interest and investment income, net	2,067	1,798	4,107	6,788
Change in fair value of related-party convertible note			(42,582)	0
Interest expense related to revenue interest liability	(12,302)	(10,925)	(39,241)	(28,154)
Change in fair value of derivative liabilities	289	1,614	7,798	20,084
Change in fair value of warrant liabilities	14,905	31,324	18,346	10,222
Other (expense) income, net	(187)	12	(506)	(25)
Total other expense, net	(11,679)	(5,499)	(98,170)	(79,684)
Loss before income taxes and noncontrolling interests	(67,309)	(85,752)	(289,514)	(354,466)
Income tax benefit	35	0	0	0
Net loss	(67,274)	(85,752)	(289,514)	(354,466)
Net loss attributable to noncontrolling interests, net of tax	(21)	(23)	(60)	(64)
Net loss attributable to ImmunityBio common stockholders	$ (67,253)	$ (85,729)	$ (289,454)	$ (354,402)
Net loss per ImmunityBio common share – basic (in dollars per share)	$ (0.07)	$ (0.12)	$ (0.32)	$ (0.52)
Net loss per ImmunityBio common share - diluted (in dollars per share)	$ (0.07)	$ (0.14)	$ (0.32)	$ (0.53)
Weighted-average number of common shares used in computing net loss per share – basic (in shares)	946,601	695,895	896,335	685,261
Weighted-average number of common shares used in computing net loss per share – diluted (in shares)	946,601	697,961	896,335	688,939
Reportable Segment
Total revenue	$ 32,061	$ 6,106	$ 75,003	$ 7,193
Operating costs and expenses
Cost of sales	177	0	371	0
Research and development	51,232	50,443	154,702	154,923
Selling, general and administrative	36,282	35,916	111,274	127,052
Loss from operations	(55,630)	(80,253)	(191,344)	(274,782)
Other income (expense), net
Interest and investment income, net	2,067	1,798	4,107	6,788
Interest expense (including amounts with related parties)	(15,282)	(29,322)	(46,092)	(88,599)
Interest expense related to revenue interest liability	(12,302)	(10,925)	(39,241)	(28,154)
Change in fair value of derivative liabilities	289	1,614	7,798	20,084
Change in fair value of warrant liabilities	14,905	31,324	18,346	10,222
Other (expense) income, net	(187)	12	(506)	(25)
Total other expense, net	(11,679)	(5,499)	(98,170)	(79,684)
Loss before income taxes and noncontrolling interests	(67,309)	(85,752)	(289,514)	(354,466)
Income tax benefit	35	0	0	0
Net loss	(67,274)	(85,752)	(289,514)	(354,466)
Net loss attributable to noncontrolling interests, net of tax	(21)	(23)	(60)	(64)
Net loss attributable to ImmunityBio common stockholders	(67,253)	(85,729)	(289,454)	(354,402)
Non-related Party
Operating costs and expenses
Research and development	48,661	48,419	147,067	148,573
Selling, general and administrative	35,508	35,091	109,347	125,121
Other income (expense), net
Interest expense (including amounts with related parties)	(26)	0	(49)	(32)
Related-Party
Operating costs and expenses
Research and development	2,571	2,024	7,635	6,350
Selling, general and administrative	774	825	1,927	1,931
Other income (expense), net
Change in fair value of related-party convertible note	(1,169)	0	(42,582)	0
Interest expense (including amounts with related parties)	(15,256)	(29,322)	(46,043)	(88,567)
Related-Party \| Reportable Segment
Other income (expense), net
Change in fair value of related-party convertible note	(1,169)	0	(42,582)	0
Product revenue, net
Total revenue	31,780	5,954	74,710	6,944
Other revenues
Total revenue	$ 281	$ 152	$ 293	$ 249

ImmunityBio, Inc. 10-Q